Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 9/20 | 0.41 |
| ▸ | F10 | P00742 | 7/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964351 | 0.84 | ROCK1 (0.54) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL3960949 | 0.82 | PI4K2A (0.48) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL2056378 | 0.82 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL4062967 | 0.80 | PDE4A (0.50) | — | |
| SCHEMBL27591606 | 0.79 | PI4K2A (0.46) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL27554442 | 0.79 | PI4K2A (0.46) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL20193924 | 0.78 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL27551026 | 0.77 | PI4K2A (0.43) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL27551287 | 0.76 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL6442231 | 0.76 | NR4A2 (0.56) | PI4KAPI4K2BPI4K2API4KBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1208097-B1 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMA INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| CN-1420882-A | Substd. oxoazaheterocyclyl compounds | AVENTIS PHARM PROD INC (US) | 2003-05-28 | — | — | CN | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | PI4KA 3175/4885PI4K2B 2871/4885PI4K2A 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.